title: Resolution of bilateral corneal neovascularization and lipid keratopathy after photodynamic therapy with verteporfin.
abstract: OBJECTIVE
  The aim of this study was to describe the result of photodynamic therapy with verteporfin (Visudyne(®), Novartis Ophthalmics AG, Hettingen, Switzerland) on bilateral corneal neovascularization (CN) and lipid keratopathy.
  
  
  METHODS
  A 36-year-old man with bilateral CN and visually significant lipid keratopathy presented to the King Khaled Eye Specialist Hospital with decreased visual acuity in both eyes; bilateral refractive surgery had been done several years before. He was wearing hard contact lenses and had a history of repeated keratitis in both eyes. Eyes were treated with nonthermal laser light at 689 nm delivered 15 minutes after an intravenous infusion of verteporfin, 6 mg/m(2) of body surface area, which was repeated 2 months after his first session. He was followed up regularly for 4 years with ophthalmic examinations and photographic documentation.
  
  
  RESULTS
  Successful occlusion of the CN was observed by the third month, and a dramatic resorption of lipid keratopathy was noticed by the end of the first year in both eyes. Best-corrected visual acuities improved from 20/80 in the right eye and 20/100 in the left eye to 20/30 with each eye. During the 4-year follow-up period, neither recurrence nor complications of the treatment was observed.
  
  
  CONCLUSIONS
  Laser therapy with verteporfin can be added to the armamentarium of treatments for CN as a safe and effective option.
authors.affiliation: Anterior Segment Division, King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia.
authors.forename: Abdulelah A
authors.initials: AA
authors.lastname: Al-Abdullah
authors.forename: Abdullah
authors.initials: A
authors.lastname: Al-Assiri
mesh_terms: D000328:Adult; D016510:Corneal Neovascularization / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D000077362:Verteporfin
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin